Literature DB >> 15958833

Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children.

Vincent Bekker1, Corine Bronke, Henriëtte J Scherpbier, Jan F Weel, Suzanne Jurriaans, Pauline M E Wertheim-van Dillen, Frank van Leth, Joep M A Lange, Kiki Tesselaar, Debbie van Baarle, Taco W Kuijpers.   

Abstract

OBJECTIVE: To analyse the effect of viral coinfections on immune reconstitution in HIV-1-infected children (< 18 years) taking highly active antiretroviral therapy (HAART).
METHODS: Absolute lymphocyte numbers of various subsets of CD8 T cells were measured.
RESULTS: Prior cytomegalovirus (CMV) infection correlated with an increased number of CD8 effector T cells (i.e., CD45RA+CD27-) at baseline (CMV-seropositive versus CMV-seronegative patients; P = 0.009), as well as an increased state of T cell activation as defined by HLA-DR and CD38 expression. The expansion of effector CD8 T cells persisted over time, independent of the HIV response to HAART. Numbers of CD8 effector T cells were significantly higher in patients with CMV replication as reflected by persistent urinary CMV shedding and periodic CMV DNAaemia (P = 0.02). These patients also showed an increase in CMV-specific antibodies compared with those without CMV shedding (P = 0.007). The number of CMV-specific interferon-gamma (IFN-gamma)-producing CD8 T cells was lower in children who persistently shed CMV compared with those who did not (P = 0.02). In contrast, CMV-specific CD4 T cell responses were detected at similar levels in both groups.
CONCLUSIONS: In HIV-1-infected children, CMV infection correlated with the outgrowth of CD8+CD45RA+CD27- effector T cells. Activation of the immune system by persistent CMV secretion resulted in increasing CMV-specific IgG and higher numbers of CD8 effector T cells. Despite these increases, the CMV-specific IFN-gamma-producing CD8 T cell response was diminished, which could explain the inability to suppress CMV completely in 41% of HIV-1-infected children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958833     DOI: 10.1097/01.aids.0000174448.25132.ad

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy.

Authors:  A Anselmi; D Vendrame; O Rampon; C Giaquinto; M Zanchetta; A De Rossi
Journal:  Clin Exp Immunol       Date:  2007-10-22       Impact factor: 4.330

2.  PD-1 expression on peripheral CD8+ TEM/TEMRA subsets closely correlated with HCV viral load in chronic hepatitis C patients.

Authors:  Tao Shen; Jiajia Zheng; Chunhui Xu; Jia Liu; Weidong Zhang; Fengmin Lu; Hui Zhuang
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

Review 3.  Immune activation and paediatric HIV-1 disease outcome.

Authors:  Julia M Roider; Maximilian Muenchhoff; Philip J R Goulder
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

4.  Regulatory function of cytomegalovirus-specific CD4+CD27-CD28- T cells.

Authors:  Adriana Tovar-Salazar; Julie Patterson-Bartlett; Renee Jesser; Adriana Weinberg
Journal:  Virology       Date:  2009-12-24       Impact factor: 3.616

5.  Cytomegalovirus and paediatric HIV infection.

Authors:  Jennifer A Slyker
Journal:  J Virus Erad       Date:  2016-10-05

6.  High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era.

Authors:  Margaret R Caplan; Eleanor M P Wilson; Melissa Schechter; Catherine W Cai; Allison Venner; Rachel Bishop; Joseph Adelsberger; Jeanette Higgins; Gregg Roby; Jing Wang; Virginia Sheikh; Irini Sereti
Journal:  J Virus Erad       Date:  2021-09-09

Review 7.  A systematic review of the impact of psychosocial factors on immunity: Implications for enhancing BCG response against tuberculosis.

Authors:  Sally E Hayward; Jennifer B Dowd; Helen Fletcher; Laura B Nellums; Fatima Wurie; Delia Boccia
Journal:  SSM Popul Health       Date:  2019-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.